BCL10 and neoplasm: demonstrated that the other fusion mutation in caspase recruitment domain-containing protein (CARD11) and Phosphoinositide-3-Kinase Regulatory Subunit 3 (PIK3R3) improved tumor killing effect by enhanced signaling of CARD11–BCL10–MALT1 complex (204).